128 related articles for article (PubMed ID: 9624477)
1. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
[TBL] [Abstract][Full Text] [Related]
2. Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.
Rayner CR; Ioannides-Demos LL; Brien JA; Liolios LL; Spicer WJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1370-4. PubMed ID: 9624478
[TBL] [Abstract][Full Text] [Related]
3. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.
Wood PJ; Ioannides-Demos LL; Bastone EB; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1996 May; 40(5):1321-4. PubMed ID: 8723496
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
5. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
Karlowsky JA; Zhanel GG; Davidson RJ; Hoban DJ
Antimicrob Agents Chemother; 1994 May; 38(5):1165-8. PubMed ID: 8067757
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
7. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
8. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
9. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
[TBL] [Abstract][Full Text] [Related]
11. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
Rees VE; Bulitta JB; Oliver A; Tsuji BT; Rayner CR; Nation RL; Landersdorfer CB
J Antimicrob Chemother; 2016 Nov; 71(11):3157-3167. PubMed ID: 27521357
[TBL] [Abstract][Full Text] [Related]
12. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
15. Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa.
Zuravleff JJ; Yu VL; Yee RB; Zaphyr MK; Diven W; Taylor FB
Antimicrob Agents Chemother; 1982 Nov; 22(5):839-43. PubMed ID: 6817707
[TBL] [Abstract][Full Text] [Related]
16. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
Canis F; Cavallo JD; Husson MO
Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
19. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
Li RC; Zhu ZY
J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
